BKHA · Black Hawk Acquisition Corp · Executive Compensation
$4.14
+0.11 (+2.73%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Oct 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of a Business Combination. In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standard Board's Accounting Standards Update ("ASU") 2014-15, "Disclosures of Uncertainties about an Entity's Ability to Continue as a Going Concern," management has determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern. In addition, if the Company is unable to complete a Business Combination within the Combination Period, the Company's board of directors would proceed to commence voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company's plans to consummate a Business Combination will be successful within the Combination Period. As a result, management has determined that such an additional condition also raises substantial doubt about the Company's ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Oct 6, 2026
Market Cap
$16.99M
Shares
4.15M
Volume · Oct 20
12.59K
Avg daily vol (3M)
25.59K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Tolentino, M.D. | Chief Executive Officer (CEO) | Appointed | 2026-03-17 |
| Luo Feng | Chief Scientific Officer | Appointed | 2026-03-17 |
| Michael Tolentino | Chief Executive Officer ("CEO") | Appointed | 2026-03-17 |
| Frederick Woodruff Field | member of its board of directors | Appointed | 2026-02-03 |
| Mitchell Creem | Chief Financial Officer of Vesicor | Appointed | 2026-02-03 |
| Terry W. Protto | Chairperson of the Compensation Committee | Appointed | 2025-06-04 |
| Daniel M. McCabe | Chairperson of the Compensation Committee | Resigned | 2025-06-04 |
| Daniel M. McCabe | Chairperson of the Audit Committee | Appointed | 2025-06-04 |
| Jonathan Ginsberg | director | Appointed | 2024-04-24 |
| Jonathan Ginsberg | Chief Operating Officer | Appointed | 2024-04-24 |
Leadership
- Michael Tolentino CEO
- Michael Tolentino, M.D. CEO
- Mitchell Creem CFO
- Jonathan Ginsberg COO, Board Member
- Frederick Woodruff Field Board Member
- Terry W. Protto Board Member